Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 open-label study in Rett syndrome
ACTRN12623000563662Phase 2Completed
- Sponsor
- Fenix Innovation Group
- Start
- Sep 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NTI164 in Rett syndrome (RTT), sponsored by Fenix Innovation Group. Primary endpoint: Change in Clinical Global Impression. Started Sep 2023; status: completed.
02
Drugs
NTI164
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on ACTRN12623000563662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000563662.